Regarding the controversy surrounding the Dong Sung Pharmaceutical rehabilitation plan, the largest shareholder, Brand Refactoring, stated on March 16 ...
Brand Refactoring revealed that it discovered evidence suggesting that the current management, including CEO Na Won-gyeon of Dong Sung Bio Pharm, Executive Director Won Yong-min, and Director Namgung ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する